NEW YORK, March 23, 2018 /PRNewswire/ —

Data published by Energias Market Research estimates that the global medical cannabis market is expected to grow significantly from USD 8.28 billion in 2017 to USD 28.07 billion in 2024, at a CAGR of 19.1% from 2018 to 2024. Factors driving the growth of the medical cannabis market include growing recognition of medical benefits, increasing demand for cannabis in the treatment of various diseases, and growing number of research and development activities. In the U.S, there are 28 states which have approved the use of cannabis for medical purposes. In major markets like Colorado, California, Alaska, Massachusetts and Nevada, cannabis is legal for recreational use. Pivot Pharmaceuticals Inc. (OTC: PVOTF), GW Pharmaceuticals plc (NASDAQ: GWPH), Cara Therapeutics Inc (NASDAQ: CARA), 22nd Century Group, Inc. (NYSE: XXII), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

According to CBC, Canada is one of only two countries, together with the Netherlands – that currently exports cannabis, allowing firms in Canada to take instant benefit of recent medical cannabis legalizations in more than 20 countries. CBC reported that the, “offerings in today’s Canada medical marijuana market differ little from those used recreationally – the smokable plant and, more recently, oil extracts. More than 70 companies have licenses from the federal drug regulator, Health Canada, to cultivate, produce and sell medical marijuana, with more than half those licenses granted in 2017 or 2018.”

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) also listed on the Canadian Stock Exchange under the Ticker ‘PVOT’. On March 19th the company announced that, “effective March 16th, 2018 the Company has been named to the CSE25 Index, a composite of the 25 largest companies, as measured by market capitalization, listed on the Canadian Securities Exchange. In addition, the Company is also a constituent of

Read More Here...